OTC erythromycin
This article was originally published in The Tan Sheet
Executive Summary
FDA's Dermatologic Drugs and Anti-Infective Drugs Advisory Committees are scheduled to meet jointly Nov. 16 at 8 a.m. at the Bethesda Holiday Inn, Bethesda, Md., to discuss the potential for development of antibiotic resistance if topical erythromycin were to be made available OTC for the treatment of acne, according to an Oct. 18 Federal Register notice ("The Tan Sheet" Oct. 10, In Brief)